# Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

> **NCT03790085** · EARLY_PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University General Hospital** · enrollment: 2700 (estimated)

## Conditions studied

- Schizophrenia
- Major Depressive Disorder
- Anxiety Disorders

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Olanzapine
- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT03790085
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 2700 (ESTIMATED)
- **Last updated:** 2018-12-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790085, "Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03790085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*